Eledon Pharmaceuticals (ELDN) Gains from Investment Securities (2024 - 2026)

Eledon Pharmaceuticals (ELDN) has 3 years of Gains from Investment Securities data on file, last reported at $19.0 million in Q1 2026.

• Quarterly Gains from Investment Securities rose 288.49% year-over-year to $19.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.4 million (up 91.85% YoY) and the FY2025 annual result came in at -$33.4 million, down 8.25% from the prior year.
• Gains from Investment Securities rose to $19.0 million in Q1 2026, from -$10.5 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $31.3 million in Q2 2024 to a low of -$96.4 million in Q3 2024.
• A 3-year average of -$7.3 million and a median of -$5.3 million in 2025 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2025 — Gains from Investment Securities plunged 150.32% — and 2026, when it surged 288.49%.
• Tracing ELDN's Gains from Investment Securities over 3 years: stood at $20.9 million in 2024, then sank by 150.32% to -$10.5 million in 2025, then soared by 280.04% to $19.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $19.0 million (Q1 2026), -$10.5 million (Q4 2025), and -$564000.0 (Q3 2025), per Business Quant data.